This technology is a preclinical tool for generating multi-target directed ligands (MTDLs) which bind several Alzheimer’s Disease related targets.
Alzheimer’s disease is a complex neurodegenerative disease with multiple pathological mechanisms acting in concert. Multi-target directed ligands (MTDLs) are drugs that act against multiple targets, which have shown promise in treating complex diseases like Alzheimer’s disease. Currently available MTDL development methods are time-consuming and costly, creating a need for a more time and resource effective pipeline for MTDL development.
This technology is a preclinical tool to both synthesize and test develop multi-target directed ligands (MTDL) using a combination of in vitro and in vivo zebrafish preclinical Alzheimer’s Disease models. These methods are more cost-effective than existing MTDL development approaches and can be scaled up as a high-throughput approach to more effectively synthesize and test large sets of compounds for therapeutic benefit in Alzheimer’s Disease and other multifactorial diseases.
This technology has been used to successfully identify and test novel MTDL compounds for a variety of disease targets including cholinesterases, sigma receptors, P2X receptors, and glutamate receptors
Patent Pending
IR CU23156, CU23303
Licensing Contact: Joan Martinez
